Can Sanofi And GSK Catch Up In mRNA Vaccines?
Pfizer And Moderna Have Head Start
GSK and Sanofi have little chance of making a big impact in COVID-19 vaccines, but hope to establish themselves in the technology in key markets such as flu.
You may also be interested in...
Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?
The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?
AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Indian Biotech In mRNA Push As COVID-19 Vaccine Moves To Phase II
Gennova Biopharma’s mRNA ambitions are taking wing as its HDT Bio-partnered self-amplifying vaccine moves to Phase II. Notably, the company will have to prove superiority to AstraZeneca/Serum Institute’s Covishield in what appears to be the first comparative study for a COVID-19 vaccine candidate in India, Scrip learns.